COLL Form 144: 17,478 vested RSUs moved to Merrill Lynch for sale

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. (COLL) Form 144 notice: An insider plans to sell 17,478 shares of common stock through Merrill Lynch, with an aggregate market value of $671,576.38. The shares represent vested restricted stock units acquired on 02/21/2025 and were transferred to a brokerage account the same day. The filing lists the approximate sale date as 08/29/2025 and identifies NASDAQ as the exchange. The filer reports no securities sold in the past three months and includes the standard signer representation that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR: Routine insider sale of vested RSUs totaling 17,478 shares, representing a modest disposition relative to outstanding shares.

The filing documents a typical Rule 144 notice: restricted stock units vested on 02/21/2025 were moved to a Merrill Lynch brokerage account and are scheduled for sale on 08/29/2025 with an indicated market value of $671,576.38. With 31,502,127 shares outstanding, this sale equals roughly 0.055% of outstanding shares, which is immaterial from a market-cap perspective. No prior sales in the past three months are reported, reducing immediate signaling concerns.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure of vested equity sale; paperwork aligns with Rule 144 and includes required seller attestations.

The notice contains required details: acquisition date, nature of acquisition (vested RSUs), transfer to broker, and planned sale date. The representation that the seller is unaware of undisclosed material adverse information and the absence of recent sales are standard and appropriate. There is no indication of plan dates, trading-plan adoption, or other complicating governance factors in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 301 N. Seminary St. Florence AL 35630	17478	671576.38	31502127	08/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/21/2025	Vested RSUs	Collegium Pharmaceutical, Inc.			17478	02/21/2025	Vested RSUs to brokerage account

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the COLl Form 144 filing?

The filing reports the proposed sale of 17,478 shares of common stock (vested RSUs) with an aggregate market value of $671,576.38.

When were the securities acquired according to the filing?

The securities were acquired (vested) on 02/21/2025 and transferred to a brokerage account the same day.

Who is the broker handling the sale listed in the Form 144?

The broker named is Merrill Lynch at the Florence, AL address provided in the filing.

What is the approximate date of sale listed in the filing?

The approximate date of sale is listed as 08/29/2025.

Does the filing report any securities sold in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

How large is the sale relative to shares outstanding?

The filing shows 31,502,127 shares outstanding; the 17,478-share sale is a very small fraction of total shares outstanding.